Article

Transcatheter aortic valve implantation for high-risk patients with severe aortic stenosis: A systematic review.

Department of Cardiothoracic Surgery, The University of Sydney, Royal Prince Alfred Hospital, Sydney 2050, Australia.
The Journal of thoracic and cardiovascular surgery (Impact Factor: 3.41). 10/2009; 139(6):1519-28. DOI: 10.1016/j.jtcvs.2009.08.037
Source: PubMed

ABSTRACT The present systematic review objectively assessed the safety and clinical effectiveness of transcatheter aortic valve implantation for patients at high surgical risk with severe aortic stenosis.
Electronic searches were performed in 6 databases from January 2000 to March 2009. The end points included feasibility, safety, efficacy, and durability. Clinical effectiveness was synthesized through a narrative review with full tabulation of results of all included studies.
The current evidence on transcatheter aortic valve implantation for aortic stenosis is limited to short-term observational studies. The overall procedural success rates ranged from 74% to 100%. The incidence of major adverse events included 30-day mortality (0%-25%), major ventricular tachyarrhythmia (0%-4%), myocardial infarction (0%-15%), cardiac tamponade (2%-10%), stroke (0%-10%), conversion to surgery (0%-8%), moderate to major paravalvular leak (4%-35%), vascular complication (8%-17%), valve-in-valve procedure (2%-12%), and aortic dissection/perforation (0%-4%). The overall 30-day major adverse cardiovascular and cerebral events ranged from 3% to 35%. The mean aortic valve area ranged from 0.5 to 0.8 cm(2) before and 1.3 to 2.0 cm(2) after transcatheter aortic valve implantation. The mean pressure gradient ranged from 34 to 58 mm Hg before and 3 to 12 mm Hg after transcatheter aortic valve implantation. There was no significant deterioration in echocardiography measurements during the assessment period. Death rate at 6 months postprocedure ranged from 18% to 48%. No studies had adequate follow-up to reliably evaluate long-term outcomes.
The procedure has a potential for serious complications. Although short-term efficacy based on echocardiography measurements is good, there is little evidence on long-term outcomes. The use of transcatheter aortic valve implantation should be considered only within the boundaries of clinical trials.

0 Bookmarks
 · 
188 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Many patients deemed inoperable for surgical aortic valve replacement (SAVR) have been treated successfully by transcatheter aortic-valve replacement (TAVR). This meta-analysis is designed to evaluate the performance of TAVR in comparison with SAVR.
    Open heart. 08/2014; 1(1):e000013.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: R ealizado pela primeira vez em 2002, o implante percutâneo de bioprótese aórtica tem despertado significativo interesse nos últimos anos, por tra-tar-se de alternativa segura e menos invasiva para pacientes portadores de estenose aórtica e alto risco cirúrgico. Atualmente, dois tipos de prótese são dispo-níveis e comercializadas na Europa e diversas outras estão sendo investigadas, e mais de 20 mil pacientes foram tratados até 2010. Vários registros têm sido pu-blicados e importantes estudos randomizados e compa-rativos com a cirurgia de troca valvar e com o tratamento conservador estão disponíveis (SOURCE, PARTNER) ou em andamento (UK TAVI Trial, SURTAVI). Em nosso País, cerca de 200 pacientes já foram submetidos ao implante da bioprótese autoexpansível CoreValve TM (Medtronic Inc., Minneapolis, Estados Unidos), e vislum-bra-se, ainda no primeiro semestre, o início da utili-zação da bioprótese balão-expansível Edwards-SAPIEN TM (Edwards Lifesciences, Irvine, Estados Unidos). Nesta edição da Revista Brasileira de Cardiologia Invasiva, somos apresentados a duas das experiências nacionais de implante valvular aórtico percutâneo. Lemos et al. 1 descrevem os resultados clínicos dos primeiros 75 pacientes tratados com a prótese CoreValve TM em dois centros, no Brasil (n = 14) e na Itália (n = 61); e Bernardi et al. 2 , por sua vez, relatam a evolução de dois anos dos primeiros 4 pacientes submetidos ao procedimento no Sul do País. Os resul-tados das duas publicações exprimem tanto os notá-veis progressos alcançados como os grandes desafios a serem transpostos para a ampliação nas indicações desse procedimento.
    Revista Brasileira de Cardiologia Invasiva. 03/2011; 19(1).
  • [Show abstract] [Hide abstract]
    ABSTRACT: Transcatheter aortic valve implantation (TAVI) has become the preferred treatment option for patients with symptomatic severe aortic stenosis who are inoperable or at high risk for surgical aortic valve replacement. TAVI has shown a clear mortality benefit compared to conservative treatment in inoperable patients, and is at least non-inferior to surgical aortic valve replacement in high-risk operable patients. Through improvements in the field of imaging, refinement in valve technologies, increasing operator and team experience and continuous valuable research, TAVI has developed rapidly in the past years and is expected to further boost in the near future. In this review, we discuss the technical and procedural aspects of TAVI, the acute and late outcomes, and highlight the current expectations and potential future development of this rapidly evolving technology.
    Expert Review of Cardiovascular Therapy 07/2014;

Full-text (2 Sources)

Download
49 Downloads
Available from
Jun 4, 2014